COVID-19大流行前、中、后苏州儿童RSV流行动态及其他病原混合阳性情况分析
收稿日期: 2024-11-11
录用日期: 2024-12-12
网络出版日期: 2025-02-27
基金资助
江苏省社会发展重点项目(BE2021656)
Analysis of RSV prevalence dynamics and mixed positivity for other pathogens among children in Suzhou before, during and after the COVID-19 pandemic
Received date: 2024-11-11
Accepted date: 2024-12-12
Online published: 2025-02-27
目的 了解新型冠状病毒肺炎(COVID-19)大流行前、中、后呼吸道合胞病毒(RSV)流行病学特征及其他病原体混合阳性情况,为完善儿童急性呼吸道感染(ARTIs)防治提供证据支持。方法 回顾性分析2016年1月至2024年5月在苏州大学附属儿童医院住院的≤16岁ARTIs患儿的病原体检测结果。分别比较COVID-19流行第一年(2020年,阶段Ⅰ)、第二和第三年(2021—2022年,阶段Ⅱ)、COVID-19流行后(2023 年1月至2024年5月,阶段Ⅲ)与疫情前期的RSV流行以及其他病原体混合阳性特征。结果 研究纳入83 356例ARTIs患儿,RSV阳性病例为11 277例(13.5%),单一RSV阳性5 605例(6.7%),RSV混合阳性5 672例(6.8%)。RSV阳性患儿中,细菌、其他病毒病原体、非典型病原体检出率分别为39.5%,13.6%和5.7%。与预测阳性率相比,2020年和2022年RSV检测阳性率有所下降,而2021年、2023年和2024年RSV检测阳性率有所上升。单一RSV阳性组与RSV混合阳性组之间年龄、流行时期和季节的分布差异均有统计学意义(P<0.001);阶段Ⅲ期,RSV与其他病原混合阳性率显著高于单一RSV阳性率,差异有统计学意义(P<0.01)。RSV阳性患儿的甲/乙型流行性感冒病毒、副流感病毒、腺病毒、人偏肺病毒、肺炎支原体、肺炎衣原体和流感嗜血杆菌检出率明显升高。结论 COVID-19大流行对RSV流行及其他病原混合阳性的诊治产生不利影响,COVID-19流行后应长期监测RSV混合其他病原阳性的复发及感染升级。
徐雪娜 , 李娇阳 , 陈苏清 , 张义祝 , 蒋吴君 , 郝创利 . COVID-19大流行前、中、后苏州儿童RSV流行动态及其他病原混合阳性情况分析[J]. 临床儿科杂志, 2025 , 43(3) : 168 -176 . DOI: 10.12372/jcp.2025.24e1204
Objective To understand the prevalence of respiratory syncytial virus (RSV) and co-positivity of other pathogens before, during and after COVID-19 pandemic, and to provide evidence-based support for improving the prevention and treatment of acute respiratory tract infections (ARTIs) in children. Methods The pathogen detection results of ARTIs children aged ≤16 years who were admitted to the Children's Hospital of Soochow University from January 2016 to May 2024 were retrospectively analyzed. The characteristics of RSV epidemics and mixed positivity for other pathogens in the first year of the COVID-19 epidemic (2020, Stage Ⅰ), the second and third years (2021-2022, Stage Ⅱ) and the post-COVID-19 epidemic (January 2023 to May 2024, Stage Ⅲ) were compared with those in the pre-epidemic period. Results The study included 83356 children with ARTIs, with 11277 (13.5%) testing positive for RSV, 5605 (6.7%) testing positive for RSV alone, and 5672 (6.8%) testing positive for RSV in combination with other respiratory pathogens. In RSV positive children, the detection rates of bacteria, other viral pathogens and atypical pathogens were 39.5%, 13.6% and 5.7%, respectively. RSV test positive rates decreased in 2020 and 2022, while RSV test positive rates increased in 2021, 2023 and 2024 compared with predicted positive rates. There were significant differences in age, epidemic period and season between single RSV positive group and mixed RSV positive group (P<0.001). In stage Ⅲ, the positive rate of RSV mixed with other pathogens was significantly higher than that of single RSV, and the difference was statistically significant (P<0.01). The detection rate of influenza A/B viruses, human parainfluenza virus, adenovirus, human metapneumovirus, Mycoplasma pneumoniae, Chlamydia pneumoniae and Haemophilus influenzae was significantly higher in children with RSV. Conclusions The COVID-19 pandemic had an adverse impact on the prevalence of RSV and the diagnosis and treatment of mixed-positive cases of other pathogens, and the resurgence of mixed-positive RSV and the escalation of infections should be monitored for a long time after COVID-19.
[1] | Mufson MA, Orvell C, Rafnar B, et al. Two distinct subtypes of human respiratory syncytial virus[J]. J Gen Virol, 1985, 66 (Pt 10): 2111-2124. |
[2] | Pangesti KNA, Abd El Ghany M, Walsh MG, et al. Molecular epidemiology of respiratory syncytial virus[J]. Rev Med Virol, 2018, 28(2). |
[3] | Thorburn K, Harigopal S, Reddy V, et al. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis[J]. Thorax, 2006, 61(7): 611-615. |
[4] | Lin HC, Liu YC, Hsing TY, et al. RSV pneumonia with or without bacterial co-infection among healthy children[J]. J Formos Med Assoc, 2022, 121(3): 687-693. |
[5] | Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study[J]. Lancet Infect Dis, 2023, 23(1): 56-66. |
[6] | Rodgers L, Sheppard M, Smith A, et al. Changes in seasonal respiratory illnesses in the United States during the coronavirus disease 2019 (COVID-19) pandemic[J]. Clin Infect Dis, 2021, 73(Suppl 1): S110-S117. |
[7] | Yeoh DK, Foley DA, Minney-Smith CA, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter[J]. Clin Infect Dis, 2021, 72(12): 2199-2202. |
[8] | Groves HE, Piché-Renaud PP, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study[J]. Lancet Reg Health Am, 2021, 1: 100015. |
[9] | Nygaard U, Hartling UB, Nielsen J, et al. Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study[J]. Lancet Child Adolesc Health, 2023, 7(3): 171-179. |
[10] | Zheng Z, Pitzer VE, Shapiro ED, et al. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US[J]. JAMA Netw Open, 2021, 4(12): e2141779. |
[11] | Chuang YC, Lin KP, Wang LA, et al. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review[J]. Infect Drug Resist, 2023, 16: 661-675. |
[12] | Jiang W, Xu L, Wang Y, et al. Exploring immunity debt: dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic[J]. J Infect, 2024, 88(1): 53-56. |
[13] | Tanne JH. US faces triple epidemic of flu, RSV, and covid[J]. BMJ, 2022, 379: o2681. |
[14] | Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity[J]. Nat Rev Microbiol, 2023, 21(3): 195-210. |
[15] | 王天有, 申昆玲, 沈颖. 诸福棠实用儿科学[M]. 第9版. 北京︰人民卫生出版社, 2022. |
Wang TY, Shen KL, Shen Y. Zhufutang practical pediatrics[M]. 9th ed. Beijing: People's Medical Publishing House, 2022. | |
[16] | Brenes-Chacon H, Garcia-Mauri?o C, Moore-Clingenpeel M, et al. Age-dependent interactions among clinical characteristics, viral loads and disease severity in young children with respiratory syncytial virus infection[J]. Pediatr Infect Dis J, 2021, 40(2): 116-122. |
[17] | Teirlinck AC, Broberg EK, Stuwitz Berg A, et al. Recommendations for respiratory syncytial virus surveillance at the national level[J]. Eur Respir J, 2021, 58(3): 2003766. |
[18] | Delestrain C, Danis K, Hau I, et al. Impact of COVID-19 social distancing on viral infection in France: a delayed outbreak of RSV[J]. Pediatr Pulmonol, 2021, 56(12): 3669-3673. |
[19] | Kuitunen I, Renko M, Tapiainen T. The end of COVID-19 restrictions for children in autumn 2021 was followed by an unusually early, high-peak respiratory syncytial virus epidemic[J]. Acta Paediatr, 2023, 112(1): 146-148. |
[20] | Lee CY, Wu TH, Fang YP, et al. Delayed respiratory syncytial virus outbreak in 2020 in Taiwan was correlated with two novel RSV-A genotype ON1 variants[J]. Influenza Other Respir Viruses, 2022, 16(3): 511-520. |
[21] | Korppi M. Mixed microbial aetiology of community-acquired pneumonia in children[J]. APMIS, 2002, 110(7-8): 515-522. |
[22] | Jiang W, Wu M, Zhou J, et al. Etiologic spectrum and occurrence of coinfections in children hospitalized with community-acquired pneumonia[J]. BMC Infect Dis, 2017, 17(1): 787. |
[23] | Kang L, Jing W, Liu J, et al. Trends of global and regional aetiologies, risk factors and mortality of lower respiratory infections from 1990 to 2019: an analysis for the Global Burden of Disease Study 2019[J]. Respirology, 2023, 28(2): 166-175. |
[24] | Inagaki K, Ansari MAY, Hobbs CV. Readmission after hospitalization with Staphylococcus aureus bacteremia in children[J]. Am J Infect Control, 2021, 49(11): 1402-1407. |
[25] | Nation ML, Manna S, Tran HP, et al. Impact of COVID-19 nonpharmaceutical interventions on pneumococcal carriage prevalence and density in Vietnam[J]. Microbiol Spectr, 2023, 11(1): e0361522. |
[26] | Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks[J]. Nat Med, 2020, 26(5): 676-680. |
[27] | Zhang RX, Chen DM, Qian Y, et al. Surges of hospital-based rhinovirus infection during the 2020 coronavirus disease-19 (COVID-19) pandemic in Beijing, China[J]. World J Pediatr, 2021, 17(6): 590-596. |
[28] | Zhang Y, Huang Y, Ai T, et al. Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China[J]. BMC Pediatr, 2021, 21(1): 202. |
[29] | Ma J, Guo P, Mei S, et al. Influence of COVID-19 pandemic on the epidemiology of Mycoplasma pneumoniae infections among hospitalized children in Henan, China[J]. Heliyon, 2023, 9(11): e22213. |
[30] | Edens C, Clopper BR, DeVies J, et al. Notes from the field: reemergence of Mycoplasma pneumoniae infections in children and adolescents after the COVID-19 pandemic, United States, 2018-2024[J]. MMWR Morb Mortal Wkly Rep, 2024, 73(7): 149-151. |
/
〈 |
|
〉 |